Cargando…

A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up

Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has...

Descripción completa

Detalles Bibliográficos
Autores principales: Terakawa, Kanako, Niikura, Takahito, Katagiri, Daisuke, Sugita, Akiho, Kikuchi, Tatsuya, Hayashi, Ayaka, Suzuki, Minami, Takano, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133896/
https://www.ncbi.nlm.nih.gov/pubmed/37103638
http://dx.doi.org/10.1007/s13730-023-00792-9
_version_ 1785031655698726912
author Terakawa, Kanako
Niikura, Takahito
Katagiri, Daisuke
Sugita, Akiho
Kikuchi, Tatsuya
Hayashi, Ayaka
Suzuki, Minami
Takano, Hideki
author_facet Terakawa, Kanako
Niikura, Takahito
Katagiri, Daisuke
Sugita, Akiho
Kikuchi, Tatsuya
Hayashi, Ayaka
Suzuki, Minami
Takano, Hideki
author_sort Terakawa, Kanako
collection PubMed
description Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has not yet been identified. In this report, we describe a case of rapidly progressive glomerulonephritis that developed after SARS-CoV-2 vaccination, in which both anti-glomerular basement membrane (anti-GBM) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) were present. The patient’s renal biopsy showed that of the 48 glomeruli in total, four showed global sclerosis and none showed segmental sclerosis. The biopsy showed 11 cellular glomerular crescents and 5 fibrocellular glomerular crescents. Renal function improved with steroids, rituximab, and plasma exchange. Approximately 9 months later, MPO-ANCA was again elevated, and the pulmonary lesions worsened, again requiring multidisciplinary treatment. This case suggests that caution should be exercised in the development of double-positive disease after vaccination, and that long-term observation may be necessary because of the possibility of relapse.
format Online
Article
Text
id pubmed-10133896
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-101338962023-04-28 A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up Terakawa, Kanako Niikura, Takahito Katagiri, Daisuke Sugita, Akiho Kikuchi, Tatsuya Hayashi, Ayaka Suzuki, Minami Takano, Hideki CEN Case Rep Case Report Although mRNA vaccines for COVID-19 are highly beneficial and are recommended for patients with kidney disease, adverse reactions in some patients after vaccination have been problematic. Various vasculitis and renal disorders have been reported after vaccination; however, a causal relationship has not yet been identified. In this report, we describe a case of rapidly progressive glomerulonephritis that developed after SARS-CoV-2 vaccination, in which both anti-glomerular basement membrane (anti-GBM) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) were present. The patient’s renal biopsy showed that of the 48 glomeruli in total, four showed global sclerosis and none showed segmental sclerosis. The biopsy showed 11 cellular glomerular crescents and 5 fibrocellular glomerular crescents. Renal function improved with steroids, rituximab, and plasma exchange. Approximately 9 months later, MPO-ANCA was again elevated, and the pulmonary lesions worsened, again requiring multidisciplinary treatment. This case suggests that caution should be exercised in the development of double-positive disease after vaccination, and that long-term observation may be necessary because of the possibility of relapse. Springer Nature Singapore 2023-04-27 /pmc/articles/PMC10133896/ /pubmed/37103638 http://dx.doi.org/10.1007/s13730-023-00792-9 Text en © The Author(s) under exclusive licence to The Japan Society of Nephrology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Terakawa, Kanako
Niikura, Takahito
Katagiri, Daisuke
Sugita, Akiho
Kikuchi, Tatsuya
Hayashi, Ayaka
Suzuki, Minami
Takano, Hideki
A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title_full A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title_fullStr A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title_full_unstemmed A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title_short A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up
title_sort case of rapidly progressive glomerulonephritis with double-positive anti-gbm antibody and mpo-anca after sars-cov-2 vaccination and relapse during 1 year follow-up
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133896/
https://www.ncbi.nlm.nih.gov/pubmed/37103638
http://dx.doi.org/10.1007/s13730-023-00792-9
work_keys_str_mv AT terakawakanako acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT niikuratakahito acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT katagiridaisuke acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT sugitaakiho acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT kikuchitatsuya acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT hayashiayaka acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT suzukiminami acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT takanohideki acaseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT terakawakanako caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT niikuratakahito caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT katagiridaisuke caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT sugitaakiho caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT kikuchitatsuya caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT hayashiayaka caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT suzukiminami caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup
AT takanohideki caseofrapidlyprogressiveglomerulonephritiswithdoublepositiveantigbmantibodyandmpoancaaftersarscov2vaccinationandrelapseduring1yearfollowup